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In this study, we aimed to examine the relationships between antibiotic resistance,
biofilm formation, and biofilm-specific resistance in clinical isolates of Acinetobacter
baumannii. The tested 272 isolates were collected from several hospitals in China during
2010–2013. Biofilm-forming capacities were evaluated using the crystal violet staining
method. Antibiotic resistance/susceptibility profiles to 21 antibiotics were assessed
using VITEK 2 system, broth microdilution method or the Kirby-Bauer disc diffusion
method. The minimum inhibitory concentration (MIC) and minimum biofilm eradication
concentration (MBEC) to cefotaxime, imipenem, and ciprofloxacin were evaluated using
micro dilution assays. Genetic relatedness of the isolates was also analyzed by pulsed-
field gel electrophoresis (PFGE) and plasmid profile. Among all the 272 isolates, 31 were
multidrug-resistant (MDR), and 166 were extensively drug-resistant (XDR). PFGE typing
revealed 167 pattern types and 103 clusters with a similarity of 80%. MDR and XDR
isolates built up the main prevalent genotypes. Most of the non-MDR isolates were
distributed in a scattered pattern. Additionally, 249 isolates exhibited biofilm formation,
among which 63 were stronger biofilm formers than type strain ATCC19606. Population
that exhibited more robust biofilm formation likely contained larger proportion of non-
MDR isolates. Isolates with higher level of resistance tended to form weaker biofilms.
The MBECs for cefotaxime, imipenem, and ciprofloxacin showed a positive correlation
with corresponding MICs, while the enhancement in resistance occurred independent
of the quantity of biofilm biomass produced. Results from this study imply that biofilm
acts as a mechanism for bacteria to get a better survival, especially in isolates with
resistance level not high enough. Moreover, even though biofilms formed by isolates with
high level of resistance are always weak, they could still provide similar level of protection
for the isolates. Further explorations genetically would improve our understanding of
these processes and provide novel insights in the therapeutics and prevention against
A. baumannii biofilm-related infections.
Keywords: Acinetobacter baumannii, biofilm, antibiotic resistance, biofilm-specific resistance, pulsed-field gel
electrophoresis
Qi et al. Biofilm and Antibiotic Resistance
INTRODUCTION
Acinetobacter baumannii is an important nosocomial pathogen
that is responsible for a wide range of human infections, resulting
in high levels of morbidity and mortality (Bergogne-Berezin
and Towner, 1996). Due to the high prevalence of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) isolates,
A. baumannii has been identified among the top seven pathogens
threatening our healthcare-delivery system and as a prime
example of unmet medical need (Talbot et al., 2006). Antibiotic
resistance is primarily the consequence of genetic transfer of
resistance genes via plasmids, and the mutation of target genes
(Andersson and Hughes, 2010). Given the tremendous capacity
for acquiring antibiotic resistance determinants, A. baumannii
may be leaving us few effective therapeutic options (Perez et al.,
2008). Moreover, this is not the only reason antibiotics fail,
and for many occasions, it may not even be the main reason
(Levin and Rozen, 2006). In fact, biofilm formation is another
effective way for bacteria to survive in the presence of antibiotics
(Hall-Stoodley et al., 2004), especially for A. baumannii which
is one of the most common bacterial causes of biofilm-related
contamination of medical devices (Singhai et al., 2012).
Biofilms are assemblages of microorganisms, encased in a
matrix, that function as a cooperative consortium. Biofilm mode
of life is a feature common to most microorganisms in natural
and medical systems which constitutes a protected mode of
growth that allows survival in hostile environments (McDougald
et al., 2012). Biofilm-specific resistance has been reported to
be significantly higher than antibiotic resistance of planktonic
bacteria (Hoyle and Costerton, 1991). Therefore, biofilm-related
infections are more difficult to clear and more prone to relapse
(Cerqueira and Peleg, 2011). The connection between biofilm
and antibiotic resistance is of considerable interest to biomedical
researchers. Notably, several studies have demonstrated that
low doses of certain antibiotics can induce biofilm formation
(Hoffman et al., 2005; Kaplan, 2011), indicating that biofilm
regulation may be involved in the global response to external
stresses, including antibiotics (Kaplan, 2011). However, it is
currently unclear whether there is a quantitative correlation
between biofilm formation and antibiotic resistance. Over the
past two decades, multiple studies have yielded conflicting
results. For example, while Abidi et al. studied 22 Pseudomonas
aeruginosa isolates and concluded that biofilm production was
significantly higher in MDR isolates (Abidi et al., 2013), Atashili
et al. failed to find a significant difference in biofilm formation
among MDR and non-MDR Staphylococcus aureus (Atashili
et al., 2014). For A. baumannii, while Gurung et al. studied
60 isolates and found a positive relationship between biofilm
formation and antibiotic resistance (Gurung et al., 2013), Perez
studied 116 isolates and detected an inverse one between
meropenem resistance and biofilm production (Perez, 2015).
Additionally, not enough reports have analyzed the quantitative
correlation between biofilm-specific resistance and antibiotic
resistance/biofilm forming capacity, and the enhancement in
resistance after biofilm formation has not been quantified either.
In this study, we examined antibiotic resistance, biofilm
formation, and biofilm-specific resistance in 272 clinical
A. baumannii isolated from patients in China. Our results not
only highlight the elegant balance between antibiotic resistance
and biofilm formation developed by this organism to enhance
its viability, but also provide information about biofilm-specific
resistance that is expected to help understanding the role of
biofilm in resistance and contribute to resolving the problem in
treatment of biofilm-related infection.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
A total of 272 strains were collected from several general hospitals
in China during 2010–2013. The collection and use of clinical
isolated strains was approved by Institutional review board (IRB)
of Academy of Military Medical Sciences, China. All strains were
capable of growth at 44◦C, and were identified as A. baumannii
using API 20 NE tests (bio-Mérieux, Marcy l’Etoile, France).
The type strain of A. baumannii (ATCC 19606) was used for
comparison in biofilm assay (Lee et al., 2008). Strains were stored
as glycerol stocks at −80◦C, and were cultivated in nutrient agar
at 37◦C for 18–20 h without shaking for further analysis.
Pulsed-Field Gel Electrophoresis (PFGE)
and Plasmid Profile
The genetic diversity and relatedness of the isolates was
analyzed by PFGE as previously described (Seifert et al.,
2005) and plasmid profile. Briefly, pure bacterial cultures were
embedded in agarose plugs and incubated in lysis buffer
followed by digestion with 20 mg/mL proteinase K. The
plugs were thoroughly washed and then digested for 3 h
with Apa I restriction endonuclease (TaKaRa, Dalian, Beijing,
China). DNA separation was performed in 0.5× TBE buffer
in a pulsed-field electrophoresis system (Chef Mapper; Bio-Rad
Laboratories, Hercules, CA, USA) with the following conditions:
temperature 14◦C; voltage 6 V/cm; switch angle 120◦; switch
ramp 5–20 s for 19 h. The size standard strain Salmonella
enterica serotype Braenderup H9812 was digested with XbaI. The
interpretation of the PFGE banding patterns was performed with
BioNumerics software version 6.0 (AppliedMaths, Sint-Martens-
Latem, Belgium). A tree indicating relative genetic similarity
was constructed based on the unweighted pair group method
of averages and a position tolerance of 1.5%. Band patterns
indistinguishable from each other were defined as one PFGE
pattern type and clusters were defined as isolates with band
patterns of 80% similarity or above.
For plasmid profile, the plugs were performed with restriction
endonuclease digestion S1 for 10min at 37◦C, and pulse time
ramped from 5 to 20 s at 6.0 V/cm for 12 h.
Antimicrobial Susceptibility Testing
Antibiotic resistance to 21 drugs covering all the nine
antimicrobial categories including aminoglycosides,
carbapenems, fluoroquinolones, penicillins + β-lactamase
inhibitors, folate pathway inhibitors, tetracyclines, penicillins,
cephems, and lipopeptides was assessed for each isolate. These
nine antimicrobial categories were epidemiologically significant
ones constructed for Acinetobacter spp. to determine MDR/XDR
in this species (Magiorakos et al., 2012).
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Minimum inhibitory concentrations (MICs) to 14 drugs
including gentamicin, tobramycin, amikacin, imipenem,
meropenem, ciprofloxacin, levofloxacin, ampicillin/sulbactam,
piperacillin/tazobactam, ceftazidime, ceftriaxone, cefepime,
trimethoprim/sulfamethoxazole, and piperacillin were assessed
on VITEK 2 system (bioM’erieux, Marcy l’Etoile, France) using
software version 5.04 and AST-GN09 test card, according to
the manufacturer’s instructions. Interpretive breakpoints for
susceptible, intermediate and resistant were consistent with
Clinical and Laboratory Standards Institute guidelines (CLSI,
2015). MICs to three drugs including polymyxin B, doxycycline
and minocycline were assessed using broth microdilution
method and resistance to four drugs including cefotaxime,
tetracycline, mezlocillin, and ticarcillin/clavulanic acid were
assessed using the standard disc diffusion method (Oxoid,
Hampshire, UK). These results were interpreted according to
CLSI (2015). Strains non-susceptible to at least one agent in three
or more antimicrobial categories were defined as MDR, while
those non-susceptible to at least one agent in all but two or fewer
antimicrobial categories were considered as XDR (Magiorakos
et al., 2012). In contrast, those resistant to 0–2 antimicrobial
categories were described separately and referred to as non-MDR
for the correlation analyses between antibiotic resistance and
biofilm formation.
Biofilm Formation Assays
The biofilm formation capacity of each strain was estimated using
the crystal violet staining method described previously (O’Toole,
2011), with minor adjustment. Briefly, strains were cultured in
nutrient agar for 18–20 h and adjusted to 0.5 McFarland units
(∼1.5 × 108 CFU/mL) with 0.85% NaCl medium. A 10-µL
aliquot of each suspension was then diluted 1:20 in 190 µL of
fresh Luria-Bertani (LB) medium in 96-well polyvinyl chloride
microtiter plates. After incubation at 37◦C for 24 h, the plates
were washed three times with 0.85% NaCl medium, and each
well was stained with 200 µL of 0.1% crystal violet (CV) for
20 min at ambient temperature. The plates were again washed
three times to remove excess stain, and the remaining CV was
solubilized by incubating with 200 µL of 95% ethanol for 20 min.
The optical density at 550 nm (OD550) of each well was then
measured (multi scanMS352, Thermo Labsystems), to obtain the
biofilm formation capacity of the isolate. ATCC 19606 was used
as a reference strain, while un-inoculated LBmediumwas used as
a negative control. All experiments were carried out in triplicate.
Since there is no universally recognized reference value used
for evaluating biofilm formation capacity (Mendoza-Olazarán
et al., 2014), in this study, strains with OD550 values greater than
that of the negative control were considered positive for biofilm
formation. Specifically, those with OD550 values greater than that
of the negative control, but less than that of the reference strain
(ATCC 19606) were characterized as weak biofilm formers, while
those with OD550 values greater than that of ATCC19606 were
considered strong biofilm formers.
Growth Rate Analysis
The growth of 12 strong and 12 weak biofilm formers were
measured (Hung et al., 2012). Strains were cultured in nutrient
agar for 18–20 h and adjusted to 0.5 McFarland units with
0.85% NaCl medium, and diluted 1: 20 in LB medium. Growth
curves were performed in triplicate, incubating for 24 h at 37◦C
with shaking at 200 rpm. Bacterial growth was monitored by
measuring the OD600 values of the culture.
Biofilm Susceptibility Test
The minimum biofilm eradication concentrations (MBECs) of
cefotaxime, imipenem and ciprofloxacin for 31 isolates were
assessed using a microdilution assay adapted from that described
by Ceri et al. (2001). The 31 strains were selected using a
systematic samplingmethod according to their biofilm formation
capacities. The test strains were cultivated in 96-well plates for
24 h at 37◦C, as described above, to allow for biofilm formation.
Biofilms were then treated with 256–524,288 µg/mL cefotaxime,
2–4096 µg/mL imipenem, and 4–8192 µg/mL ciprofloxacin
respectively for 24 h at 37◦C, rinsed, and incubated with fresh
LB medium for 24 h at 37◦C to allow for recovery. The
minimum antibiotic concentration at which no viable cell counts
were recovered from the biofilm material (OD600 < 0.1) was
considered the MBEC. All assays were repeated in triplicate.
Statistical Analyses
OD values were expressed either as means± standard deviations
(SDs) or as median values (interquartile range, IQR) based on
the distribution and the homogeneity of variance. Spearman’s
rank correlation tests was used for intergroup comparisons,
specifically, comparison of biofilm formation among isolates
susceptible, resistant to one, two antimicrobial categories,
MDR and XDR, among isolates susceptible, intermediate
and resistant to each antibiotic, comparison of antibiotic
resistance/biofilm formation among isolates with different
plasmid profiles, as well as correlations between MICs and
MBECs, MICs and biofilm formation, and enhancement in
resistance after biofilm formation and the level of biomass
produced. Wilcoxon rank sum test was used for comparison of
biofilm formation between isolates susceptible/non-susceptible
to each antimicrobial category. Data analyses were performed
using SPSS for Windows version 19.0 (SPSS Statistics, Inc.,
Chicago, IL, USA). P < 0.05 was considered statistically
significant for all tests.
RESULTS
Antimicrobial Susceptibility Testing
Resistance to mezlocillin was the most common (213, 78.3%),
followed by cefotaxime (188, 69.1%), ciprofloxacin (179, 65.8%),
piperacillin (173, 63.6%), ticarcillin/clavulanic acid (171, 62.9%),
ceftriaxone (171, 62.9%), ceftazidime (166, 61.0%), tetracycline
(165, 60.7%), trimethoprim/sulfamethoxazole (163, 59.9%),
gentamicin (162, 59.6%), cefepime (162, 59.6%), doxycycline
(162, 59.6%), imipenem (161, 59.2%), meropenem (161, 59.2%),
ampicillin/sulbactam (158, 58.1%), tobramycin (154, 56.6%),
piperacillin/tazobactam (133, 48.9%), levofloxacin (125, 46.0%),
minocycline (77, 28.3%), amikacin (61, 22.4%), and polymyxin B
(ten, 3.7%). Approximately 60% of the strains were resistant to at
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least one of the carbapenems antibiotics tested, which included
imipenem and meropenem here (Figure 1A).
No isolate was resistant to all of the 21 antibiotics. Of the
272 A. baumannii isolates tested, 268 were resistant to at least
one antibiotic. Specifically, 18 and 53 isolates were resistant to
only one or two of the 21 antibiotics tested, respectively, 31
were classified as MDR, and 166 were classified as XDR. As
such, ∼72.4% of the 272 isolates were either MDR or XDR
(Figure 1B).
Biofilm Formation and Growth Rate
Analysis
The biofilm-forming capacity of each isolate is summarized
in Figure 2A. The OD550 values for the reference strain
(ATCC19606) and negative control were 0.322 ± 0.048 and
0.080 ± 0.001, respectively. The OD550 values for the clinical
isolates ranged from 0.078± 0.003 to 2.556± 0.137. The resulting
distribution was positively skewed, and the median value (IQR)
was 0.118 (0.095, 0.270). In total, 249 (91%) isolates were positive
for biofilm formation, and 63 (23%) isolates exhibited more
robust biofilm formation than ATCC 19606. No significant
difference in growth rate of the strong and weak biofilm formers
was observed (Figure S3) indicating that the difference in biofilm
formation was not due to the growth rate.
Genotyping Profiles
PFGE typing revealed that apart from two isolates which were
not typeable, there were 167 pattern types among the remaining
270 isolates. With a similarity of 80%, all isolates formed a total
of 103 clusters (Figure S1). One-hundred-and-fifty of the 197
MDR/XDR strains were classified into the only eight clusters
containing more than five isolates: cluster4 (n = 16), cluster6 (n
= 27), cluster7 (n = 20), cluster9 (n = 48, including two non-
MDR isolates) cluster10 (n = 17), cluster11 (n = 13), cluster22
(n = 6), and cluster34 (n = 6, including one non-MDR isolate).
The remaining 23% of the MDR/XDR and 97% of the non-
MDR isolates were distributed in a scattered pattern. Such results
indicated a high genetic diversity among theA. baumannii strains
in China, meanwhile MDR and XDR isolates built up the main
prevalent genotypes.
Plasmids were detected in 255 (93.8%) isolates, among
which 152 isolates harbored one plasmid, 58 isolates harbored
two, 36 isolates harbored three, four isolates harbored four,
one isolate harbored five, one isolate harbored six, and three
isolates harbored seven. The plasmids ranged from 5.28 to
207.6 kbp in size. Resistant isolates were more likely harboring
more plasmids (P < 0.05). But no significant correlation were
found between biofilm forming capacity and plasmid harbored
(P > 0.05). Strains with the same plasmid profile could have
obviously different resistance phenotypes and biofilm forming
capacities, and strains with different plasmid profiles may have
the same resistance phenotype and biofilm forming capacity
(Figure S2).
Antibiotic-Susceptible Isolates Tended to
Form Stronger Biofilms than Resistant
Strains
To explore if there’s any correlation between biofilm formation
and antibiotic resistance, we first analyzed the composition
of the biofilm formation groups with respect to resistance
phenotypes. Among the 63 strong biofilm-formers, 79.4% were
non-MDR isolates and, 20.6% were MDR/XDR ones. The 186
weak biofilm-formers consisted of 12.4% non-MDR and 87.6%
MDR/XDR isolates. The 23 strains that were negative for biofilm
formation consisted of 8.7% non-MDR and 91.3% MDR/XDR
isolates (Figure 2B). These constituent ratios revealed that
the population that exhibited more robust biofilm formation
likely contained larger proportion of non-MDR isolates The
Spearman’s correlation coefficient (rs) for this comparison
was−0.601 (P < 0.001).
Next we found that non-MDR A. baumannii isolates
tended to form stronger biofilms than MDR and XDR strains;
this conclusion was also confirmed by statistical analyses
FIGURE 1 | Antibiotic resistance phenotypes of A. baumannii isolates examined in this study. (A) The resistance rate of all strains to 16 of the 21 antibiotics
were above 50%. (B) Approximately 72.4% of the isolates exhibited multidrug or extensively drug resistance.
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FIGURE 2 | Biofilm formation of A. baumannii isolates examined in this study. OD550, optical density at 550 nm, represents biofilm forming capacity. (A) The
level of biofilm formation was assessed for each isolate. Strains were divided into three groups according to their antibiotic resistance phenotypes:
non-multidrug-resistant (non-MDR), multidrug-resistant (MDR), and extensively drug-resistant (XDR). The red line shows the optical density at 550 nm (OD550) of the
biofilm biomass produced by the reference strain (ATCC 19606). Larger proportion of non-MDR isolates tended to form stronger biofilms (higher OD550 values).
(B) Distribution of resistance phenotypes among different biofilm production capacities displayed as a percentage stacked bar graph. Population that exhibited more
robust biofilm formation likely contained larger proportion of non-MDR isolates. (C) Distribution of biofilm formation of isolates with different resistance phenotypes.
Isolates with higher level of resistance tended to form weaker biofilms.
(rs = −0.720, P < 0.001; Table 1, Figure 2C), indicating a
negative correlation between biofilm formation capacity and
antibiotic resistance phenotypes. Non-MDR isolates were of
greater possibility to be strong biofilm producers than MDR or
XDR ones. Considered that a majority of the MDR/XDR strains
belonged to eight main PFGE clusters and they were all weak or
negative in biofilm formation, we analyzed the dataset excluding
the isolates in these clusters in case they had an impact on the
result. But we found the correlation between biofilm formation
and resistance phenotypes still exist (rs =−0.468, P < 0.001).
Finally, to determine whether biofilm formation is correlated
with resistance to any particular antibiotic(s), we compared the
biofilm forming capacities among strains with different resistance
profiles to each of the 21 antibiotics. The results revealed
that apart from polymyxin B, for each antibiotic, susceptible
isolates could form stronger biofilms than intermediate and
resistant ones, meaning a negative correlation between biofilm
quantity and resistance profile to each of the 20 antibiotics
(rs = 0.284–0.730, P < 0.001; Table 2). For polymyxin B,
no significant correlation was observed (rs = 0.046, P =
0.455; Table 2). The correlation between biofilm and resistance
to the nine antimicrobial categories was analyzed as well. For
seven of the categories including aminoglycosides, carbapenems,
fluoroquinolones, penicillins + β-lactamase inhibitors, folate
pathway inhibitors, tetracyclines, and penicillins, susceptible
isolates could form stronger biofilms than non-susceptible ones
(P < 0.001; Figures 3A–G). While for cephems and lipopeptides,
no significant difference in biofilm formation between susceptible
TABLE 1 | Biofilm forming capacities of A. baumannii with different
antibiotic resistance phenotypes.
Resistance phenotype N OD550* rs P-value
Non-MDR 75 0.439 (0.234, 0.890) −0.720 <0.001
MDR** 31 0.266 (0.139, 0.488)
XDR** 166 0.100 (0.087, 0.117)
*OD550, optical density at 550 nm; data shown inmedian (interquartile range, IQR); **MDR,
multidrug-resistant; XDR, extensively drug-resistant.
and non-susceptible isolates was observed (Figures 3H,I). We
supposed this was because of the huge difference in sample size.
For cephems, 267 isolates were non-susceptible and only five
were susceptible. For lipopeptides, which also means polymyxin
B mentioned above, 262 isolates were susceptible and only 10
were non-susceptible.
Strong and Weak Biofilms Provided Similar
Levels of Enhancement in Antibiotic
Resistance
To assess whether biofilm-specific resistance is dependent on
the quantity of biofilm biomass produced and/or on antibiotic
resistance in planktonic mode, we determined the MBECs
of cefotaxime, imipenem and ciprofloxacin for the sampled
31 A. baumannii isolates. The MICs of cefotaxime for these
isolates ranged from 0.5 to 1024 µg/mL (Figure 4). Additionally,
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TABLE 2 | Correlation between the level of biofilm formation and resistance to 21 antibiotics in A. baumannii clinical isolates.
Antimicrobial category Antimicrobial agent OD550* rs P-value
S** I** R**
Aminoglycosides Gentamicin 0.366 (0.177, 0.687) 0.090 (0.084, 0.109) 0.100 (0.089, 0.119) −0.647 <0.001
Tobramycin 0.329 (0.138, 0.643) 0.745 (0.416, 0.788) 0.100 (0.089, 0.118) −0.603 <0.001
Amikacin 0.129 (0.097, 0.392) 0.105 (0.088, 0.109) 0.105 (0.087, 0.122) −0.284 <0.001
Carbapenems Imipenem 0.360 (0.156, 0.679) 0.117 (0.117, 0.117) 0.100 (0.088, 0.117) −0.674 <0.001
Meropenem 0.360 (0.156, 0.679) 0.125 (0.125, 0.125) 0.100 (0.088, 0.117) −0.674 <0.001
Fluoroquinolones Ciprofloxacin 0.398 (0.200, 0.751) 0.440 (0.374, 0.758) 0.100 (0.088, 0.120) −0.690 <0.001
Levofloxacin 0.372 (0.187, 0.700) 0.108 (0.088, 0.124) 0.099 (0.088, 0.113) −0.662 <0.001
Penicillins + β-lactamase inhibitors Ampicillin/sulbactam 0.380 (0.200, 0.704) 0.112 (0.097, 0.132) 0.100 (0.088, 0.117) −0.709 <0.001
Piperacillin/tazobactam 0.337 (0.139, 0.666) 0.110 (0.094, 0.120) 0.103 (0.087, 0.119) −0.573 <0.001
Ticarcillin/clavulanic acid 0.412 (0.233, 0.761) 0.102 (0.097, 0.115) 0.100 (0.088, 0.119) −0.705 <0.001
Cephems Ceftazidime 0.400 (0.204, 0.737) 0.231 (0.132, 0.422) 0.100 (0.087, 0.116) −0.730 <0.001
Ceftriaxone 0.359 (0.187, 0.652) 0.400 (0.234, 0.846) 0.100 (0.088, 0.117) −0.704 <0.001
Cefotaxime 0.329 (0.121, 0.417) 0.400 (0.218, 0.824) 0.103 (0.089, 0.124) −0.625 <0.001
Cefepime 0.404 (0.231, 0.761) 0.094 (0.085, 0.118) 0.101 (0.088, 0.119) −0.673 <0.001
Folate pathway inhibitors Trimethoprim/sulfamethoxazole 0.342 (0.139, 0.682) − 0.103 (0.090, 0.121) −0.556 <0.001
Lipopeptides Polymyxin B 0.118 (0.095, 0.269) − 0.105 (0.092, 0.138) −0.046 0.455
Tetracyclines Tetracycline 0.395 (0.177, 0.793) 0.095 (0.085, 0.112) 0.137 (0.089, 0.124) −0.574 <0.001
Doxycycline 0.378 (0.177, 0.704) 0.188 (0.130, 0.275) 0.100 (0.087, 0.118) −0.688 <0.001
Minocycline 0.205 (0.010, 0.478) 0.099 (0.085, 0.116) 0.105 (0.089, 0.121) −0.424 <0.001
Penicillins Piperacillin 0.389 (0.208, 0.696) 0.535 (0.288, 0.840) 0.100 (0.088, 0.118) −0.724 <0.001
Mezlocillin 0.474 (0.336, 0.940) 0.407 (0.172, 0.633) 0.107 (0.090, 0.137) −0.511 <0.001
*OD550, optical density at 550 nm; data shown in median (interquartile range, IQR); **R, resistance; I, intermediate; S, susceptible.
the MBECs of cefotaxime for these isolates were as high as
256–524,288 µg/mL, which was 8–2048-fold higher than their
respective MIC values. For imipenem, the MIC ranged from 0.25
to 128µg/mL andMBECs ranged from 8 to 4096µg/mL, 32-512-
fold higher than their respective MIC values. For ciprofloxacin
the MICs ranged from 0.25 to 256 µg/mL and MBECs ranged
from 8 to 8192 µg/mL, 16-512-fold higher than their respective
MIC values.
We first analyzed the correlation between MIC values of
the three antibiotics and the biofilm-forming capacities of
the 31 strain and found negative correlation between the
two qualities (rs = −0.713 − −0.789, P < 0.001), further
indicating the inverse relationship between biofilm formation
and resistance to even one antibiotic. Subsequently, by assessing
the relationship between MIC and MBEC values, we detected a
positive correlation between antibiotic resistance (MIC values)
and biofilm-specific resistance (MBEC values) for the three
antibiotics (rs = 0.844 − 0.921, P < 0.001). As depicted in
Figure 4, there was a similar level of enhancement in resistance
after biofilm formation among the majority of the isolates tested.
Spearman’s rank correlation analysis indicated that for each of
the three antibiotics, this enhancement in resistance occurred
independent of the level of biomass produced (rs = −0.263 −
0.295, P > 0.05).
DISCUSSION
Antibiotic resistance in A. baumannii is an issue of increasing
concern. In this study, the prevalence of MDR and XDR isolates
was∼72.4%. These isolates also accounted for the main epidemic
clusters detected. Non-MDR population did not form into
clusters containing more than two isolates (Figure S1). The rate
of carbapenems resistance in A. baumannii is also increasing
during the past two decades in China. In the period of 1993–
2003, the reported rate was 5%, while by 2004, the rate increased
dramatically to 20–50% (Wang et al., 2007), and in this study,
we found the carbapenems resistance rate was up to 60%.
Furthermore, the prevalence of biofilm-forming strains among
the tested A. baumannii isolates was greater than 91%. These
data emphasized the importance of further research to develop
treatments against A. baumannii infections.
Here, we analyzed the antibiotic resistance and biofilm
forming potential of A. baumannii strains, and came to several
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FIGURE 3 | Relationship between biofilm formation and the resistance of A. baumannii isolates to each of the nine antimicrobial categories. OD550,
optical density at 550 nm, represents biofilm forming capacity. (A–G): For aminoglycosides, carbapenems, fluoroquinolones, penicillins + β-lactamase inhibitors, folate
pathway inhibitors, tetracyclines, and penicillins, susceptible isolates tended to form stronger biofilms (higher OD550 values) than non-susceptible ones. (H,I): For
cephems and lipopeptides, no significant difference in biofilm formation among susceptible and non-susceptible isolates was observed.
findings. First, the population that exhibited more robust biofilm
formation likely contained larger proportion of non-MDR
isolates. Second, the MDR and XDR isolates, though belonging
to different PFGE clusters, tended to form weaker biofilms
than non-MDR strains. Third, we noticed special cases from
PFGE analysis. For example, the only two non-MDR isolates in
cluster9 were among the four strongest biofilm formers in this
cluster and the one non-MDR isolate in cluster34 was also the
strongest biofilm former in this cluster. Together, these results
indicated that for A. baumannii, there was a statistically negative
correlation between antibiotic resistance and biofilm forming
capacity.
Rodriguez-Bano et al. previously reported that for
A. baumannii, biofilm-forming isolates were less frequently
resistant to imipenem and ciprofloxacin, indicating that these
strains are not as dependent on antimicrobial resistance as
non-biofilm-forming strains for survival (Rodríguez-Baño et al.,
2008) which is consistent with our result. Moreover, exposure to
sub-MIC levels of certain antibiotics promotes biofilm formation
of Staphylococcus aureus, indicating that biofilms tend to be
stronger when resistance is challenged (O’Neill et al., 2008;
Kaplan, 2011). In this study, biofilm-forming capacity was
measured in the absence of antibiotic-mediated stress. Therefore,
our findings indicate that in A. baumannii, more susceptible
isolates inherently tended to produce stronger biofilms. Together,
we think biofilm acts as a mechanism for bacteria to get a better
survival, especially in cases of when resistance level is not high
enough. While the mechanisms that govern this process are not
clear yet, expression of the β-lactamase gene blaTEM−1 is known
to inhibit biofilm formation of P. aeruginosa by perturbing cell
adhesion, thereby establishing a genetic link between biofilm
production and antimicrobial resistance (Gallant et al., 2005).
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FIGURE 4 | Resistance in A. baumannii to cefotaxime, imipenem, and ciprofloxacin during planktonic and biofilm growth. (A) Cefotaxime. (B) Imipenem.
(C) Ciprofloxacin. For these three antibiotics, biofilm-specific resistance (MBEC) was consistently higher in isolates with higher antibiotic resistance of planktonic
bacteria (MIC). The enhancement in resistance after biofilm formation occurred independent of biofilm quantity.
The presence of plasmids was also known to be associated
with both antibiotic resistance and biofilm formation. They
could enhance the ability of transferring resistance markers by
transformation or conjugation (Sherley et al., 2004). Meanwhile,
genes encode the protein of flagella and fimbriae are also
located in plasmids. These two structures could facilitate biofilm
formation (Karch et al., 1987). In this study, we found isolates
with higher level of resistance always harbored more plasmids.
But no obvious difference in biofilm formation was observed
among strains with different plasmid profiles. Further analyses
including detailed plasmid map are needed to figure out the
influence of plasmid on the relationship between these two
capacities. Explorations of beta-lactamase activity in different
conditions and find genetic links between biofilm and antibiotic
resistance other than blaTEM−1 are required to fully elucidate the
mechanisms involved in these processes.
The analyses of the MICs and MBECs were also consistent
with previous reports showing that biofilm population exhibit
enhanced antimicrobial resistance compared to planktonic
populations (Cernohorská and Votava, 2004). Specifically,
our results demonstrated that most of the A. baumannii
isolates (30/31) within biofilms exhibited 64–2048-fold greater
resistance to cefotaxime than those under planktonic growth
conditions. For imipenem and ciprofloxacin, the resistance
could increase 32–512-fold and 16–512-fold, respectively. More
importantly, we found that the increase in resistance of
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the three antibiotics occurred independent of the quantity
of biofilm biomass produced. Previous studies demonstrated
that mutations within the ndvB gene of P. aeruginosa,
which encodes a glucosyltransferase, resulted in increased
sensitivity of P. aeruginosa biofilms to several antibiotics
without affecting the biofilm-forming capacity of the organism
(Mah et al., 2003; Zhang et al., 2013). Spoering and Lewis
(2001) suggested that more persisters led to greater resistance
in P. aeruginosa biofilms. These findings genetically indicate
that biofilm-specific resistance could be regulated independent
of biofilm quantity, which is consistent with our results.
In fact, the positive correlation detected between the MIC
and MBEC values suggest that biofilm-specific resistance is
primarily dependent on the level of antibiotic resistance of
the organism and that the enhancement may be mainly the
consequence of persisters and/or genetic factors described
above. This is worth-noticing because for MDR/XDR isolates,
even though their biofilms are always quite weak, they could
still get a huge enhancement in resistance after biofilm
formation.
In conclusion, although there are individual differences
among the isolates, the results in this study indicate the existence
of correlation between antibiotic resistance, biofilm formation,
and biofilm-specific resistance statistically in A. baumannii.
The findings raise questions regarding the mechanisms through
which bacteria maintain a balance between biofilm formation
capacity and antibiotic resistance, as well as how resistant
strains achieve high levels of biofilm-specific resistance despite
producing weak biofilms. Deeper explorations of plasmid
maps and genetic regulation, such as identification of genes
involved in biofilm-specific resistance and persisters, would
improve our understanding of these processes. Clarifying
these mechanisms could provide novel insights that would
facilitate the development of therapeutics and prevention against
A. baumannii biofilm-related infections.
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